Scheckelhoff Mark R, Telford Sam R, Hu Linden T
Tufts-New England Medical Center, Tupper Research Institute, Division of Geographic Medicine and Infectious Diseases, Box 41, 750 Washington St., Boston, MA 02111, USA.
Vaccine. 2006 Mar 10;24(11):1949-57. doi: 10.1016/j.vaccine.2005.10.044. Epub 2005 Nov 4.
Lyme disease is caused by the spirochete Borrelia burgdorferi, which is transmitted through the bite of infected Ixodes ticks. Vaccination of mice with outer surface protein A (OspA) of B. burgdorferi has been shown to both protect mice against B. burgdorferi infection and reduce carriage of the organism in feeding ticks. Here we report the development of a murine-targeted OspA vaccine utilizing Vaccinia virus to interrupt transmission of disease in the reservoir hosts, thus reducing incidence of human disease. Oral vaccination of mice with a single dose of Vaccinia expressing OspA resulted in high antibody titers to OspA, 100% protection of vaccinated mice from infection with B. burgdorferi, and significant clearance of B. burgdorferi from infected ticks fed on vaccinated animals. The results indicate the vaccine is effective and may provide a manner to reduce incidence of Lyme disease.
莱姆病由伯氏疏螺旋体引起,该螺旋体通过感染的硬蜱叮咬传播。用伯氏疏螺旋体的外表面蛋白A(OspA)对小鼠进行疫苗接种已显示既能保护小鼠免受伯氏疏螺旋体感染,又能减少进食蜱中该病原体的携带量。在此我们报告一种利用痘苗病毒的靶向小鼠的OspA疫苗的研发,以阻断疾病在储存宿主中的传播,从而降低人类疾病的发病率。用单剂量表达OspA的痘苗病毒对小鼠进行口服疫苗接种,产生了高滴度的抗OspA抗体,100%保护接种疫苗的小鼠免受伯氏疏螺旋体感染,并且从以接种疫苗动物为食的感染蜱中显著清除了伯氏疏螺旋体。结果表明该疫苗有效,并可能提供一种降低莱姆病发病率的方法。